Sigyn Therapeutics (SIGY) Payables (2016 - 2025)

Sigyn Therapeutics has disclosed Payables across 10 years of filings, most recently posting $3.3 million for Q3 2025.

• In Q3 2025, Payables rose 36.65% year-over-year to $3.3 million; the TTM figure through Sep 2025 stood at $3.3 million (up 36.65% YoY), while the FY2024 annual figure was $2.5 million, up 6.24% from the prior year.
• Payables came in at $3.3 million for Q3 2025 at Sigyn Therapeutics, up from $3.0 million in the prior quarter.
• In the past five years, Payables ranged from a high of $3.3 million in Q3 2023 to a low of $622314.0 in Q1 2021.
• Average Payables over 5 years is $2.1 million, with a median of $2.4 million recorded in 2023.
• Year-over-year, Payables slumped 65.87% in 2021 and surged 203.66% in 2023.
• Over 5 years, Payables stood at $686876.0 in 2021, then soared by 185.96% to $2.0 million in 2022, then grew by 19.82% to $2.4 million in 2023, then rose by 6.24% to $2.5 million in 2024, then jumped by 31.32% to $3.3 million in 2025.
• Per Business Quant data, the three most recent Payables figures were $3.3 million in Q3 2025, $3.0 million in Q2 2025, and $2.9 million in Q1 2025.